Switching from Mounjaro to Retatrutide: What the Evidence Actually Shows

Why the evidence base for retatrutide looks different from Mounjaro's

Mounjaro entered the UK market with a substantial clinical programme behind it. SURMOUNT-1, a 72-week randomised trial involving 2,539 adults with obesity, reported an average body-weight reduction of around 20–21% at the 15 mg maintenance dose, results that underpinned the NICE appraisal published in December 2024 (NICE technology appraisal TA1026). Retatrutide has not reached that stage. Its most detailed published data comes from a phase 2 dose-finding trial, also reported in the New England Journal of Medicine, in which the highest doses produced average weight reductions of roughly 17–24% over 48 weeks in participants without type 2 diabetes. Those figures attracted considerable attention precisely because they are higher than anything previously reported at phase 2 for a weight-loss compound.

The mechanistic reason is worth understanding. Mounjaro activates two receptors: GLP-1 and GIP. Retatrutide is a triple agonist, adding glucagon receptor activation to both of those pathways. In theory, the glucagon component drives additional energy expenditure on top of appetite reduction. Whether that translates into meaningfully greater long-term clinical benefit at the population level is exactly what the ongoing phase 3 programme is designed to test. Phase 2 trials are not designed to prove efficacy at scale; they establish dose ranges and tolerability. Treating phase 2 retatrutide data as equivalent to phase 3 tirzepatide data involves a comparison the trial designs do not support.

For anyone currently taking Mounjaro and wondering whether retatrutide would serve them better, the honest answer from the evidence is: we do not yet know, and no prescriber can responsibly make that recommendation today.

What switching from tirzepatide to retatrutide would actually require

The question of switching from retatrutide to tirzepatide, or vice versa, will only become meaningful once retatrutide holds a licence. In the UK, that means an MHRA marketing authorisation, a process that follows successful phase 3 trials, a full dossier submission, and regulatory review. No timeline for UK approval has been confirmed as of summer 2026. Until then, retatrutide cannot be legally prescribed or dispensed by any registered UK pharmacy, including ours.

When and if that changes, a switch between the two medicines would not be a simple like-for-like swap. Both target overlapping receptor pathways, which raises questions about washout, dose equivalence, and tolerability during transition. A person well-established on a high Mounjaro dose would not automatically start retatrutide at its highest available strength; any transition would involve a prescriber reviewing current response, tolerability history, comorbidities, and the specific licensed protocol for the new medicine. The clinical considerations involved in switching from tirzepatide to retatrutide deserve their own careful look rather than a quick answer.

This is also why our clinical team reviews every patient before any change to treatment. That review exists precisely for moments of transition, whether someone is moving from an older medicine to Mounjaro or, in time, exploring newer options as they become available. Our prescribers meet you where you are, not where the headlines are.

How Mounjaro and retatrutide compare on what we know

The table below sets out the key facts side by side. Numbers for retatrutide are drawn from phase 2 data only and are not directly comparable to Mounjaro's phase 3 results.

A detailed side-by-side of the two medicines on efficacy, mechanism and tolerability is covered in our retatrutide versus Mounjaro comparison. That page also addresses how the glucagon pathway might affect things like metabolic rate and lean-mass preservation, areas where the trial data is still limited.

What to do if you are currently on Mounjaro and want to discuss your options

Most people asking about switching from Mounjaro to retatrutide are doing so from a reasonable place: they have heard that retatrutide may produce greater weight loss, and they want to know whether it could be the right next step. That curiosity is worth taking seriously, not dismissing. The clinical answer right now is that the right next step for someone not reaching their goals on Mounjaro is more likely a structured review of their current dose, their diet and activity patterns, and whether the maximum tolerated dose has genuinely been reached. The NICE guidance for tirzepatide notes that continuation should be reviewed if less than 5% weight reduction has occurred after six months at the highest tolerated dose, which is a useful clinical benchmark rather than a reason to wait indefinitely.

If retatrutide eventually receives UK marketing authorisation, decisions about switching from tirzepatide to retatrutide will be made in exactly the same way as any other treatment change: through a clinical consultation, with a prescriber who knows your history. There is no shortcut that is both legal and safe. Some people moving to Mounjaro from other medicines, including those switching from orlistat or moving from a single GLP-1 agent, will recognise that those transitions required the same careful approach.

Which medicine suits you is a clinical decision our prescribers make with you. If you would like to explore what is available and clinically appropriate right now, speak to our prescribers through a free consultation, reviewed the same day, with no waiting list.